Skip to main content

Andrew A. Strasser, University of Pennsylvania

How Human Laboratory Studies Can Inform FDA Tobacco Policy: Andrew Strasser, an APPC distinguished research fellow, is Assistant Professor in the Department of Psychiatry and a member of the Abramson Cancer Center at the University of Pennsylvania. He is Principal Investigator of an NCI RO1 to examine how smokers use reduced-nicotine cigarettes and how usage patterns affect toxin exposure. Dr. Strasser’s research on tobacco harm includes the effect that cigarette design features have on smoking behaviors and toxin exposure. Dr. Strasser also conducts laboratory-based research on what makes cigarette advertising and anti-tobacco public service announcements effective.

About the Speaker

Andrew Strasser is Assistant Professor in the Department of Psychiatry and a member of the Abramson Cancer Center at the University of Pennsylvania. He is Principal Investigator of an NCI RO1 to examine how smokers use reduced-nicotine cigarettes and how usage patterns affect toxin exposure. Dr. Strasser’s research on tobacco harm includes the effect that cigarette design features have on smoking behaviors and toxin exposure. Dr. Strasser also conducts laboratory-based research on what makes cigarette advertising and anti-tobacco public service announcements (PSAs) effective. Dr. Strasser was one of six worldwide recipients of the Pfizer-funded, peer-reviewed Global Research Award for Nicotine Dependence (GRAND) program. In this project, Dr. Strasser is investigating the effect of extended Varenicline use on the extinction of smoking behaviors. Results from this study may have health implications on maximizing success of smoking cessation attempts by examining individual smoking patterns.